Amgen (AMGN) Stock Price, News & Analysis

Company Overview

Amgen Inc. is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California. The company serves patients and healthcare providers in the United States and international markets through its research, manufacturing and commercial operations. Amgen is led by Chairman and Chief Executive Officer Robert A. Bradway.

Key Stats

• Today's Range: $457.36 to $468.27
• 50-Day Range: $375.65 to $451.83
• 52-Week Range: $288.00 to $468.27
• Volume: 2.95 million shs
• Average Volume: 2.75 million shs
• Market Capitalization: $249.09 billion
• P/E Ratio: 28.63
• Dividend Yield: 2.19%
• Price Target: $389.71
• Consensus Rating: Hold

Amgen Stock Analysis - MarketRank™

Amgen scored higher than 74% of companies evaluated by MarketBeat, and ranked 160th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Amgen has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 1 strong buy rating, 10 buy ratings, 16 hold ratings, and 3 sell ratings.

Downside Risk

Amgen has a consensus price target of $389.71, representing about 14.9% downside from its current price of $458.13.

Amount of Analyst Coverage

Amgen has been the subject of 23 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 7.19%

Earnings Growth

Earnings for Amgen are expected to grow by 7.19% in the coming year, from $22.96 to $24.61 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amgen is 28.46, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.08.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amgen is 28.46, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 37.09.

Price to Earnings Growth Ratio

Amgen has a PEG Ratio of 3.21. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Amgen has a P/B Ratio of 28.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.50% of the float of Amgen has been sold short.

Short Interest Ratio / Days to Cover

Amgen has a short interest ratio ("days to cover") of 4.97.

Change versus previous month

Short interest in Amgen has recently decreased by 4.63%, indicating that investor sentiment is improving.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Amgen pays a meaningful dividend of 2.29%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Amgen has been increasing its dividend for 14 years.

Dividend Coverage

The dividend payout ratio of Amgen is 62.65%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Amgen will have a dividend payout ratio of 40.96% next year. This indicates that Amgen will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.44

News Sentiment

Amgen has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 56 news articles for Amgen this week, compared to 9 articles on an average week.

Search Interest

Only 34 people have searched for AMGN on MarketBeat in the last 30 days. This is a decrease of -3% compared to the previous 30 days.

MarketBeat Follows

27 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,540,926.00 in company stock.

Percentage Held by Insiders

0.85% of the stock of Amgen is held by insiders.

Percentage Held by Institutions

76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Record date for 9/11 Dividend: 8/21/2026
• Ex-Dividend for 9/11 Dividend: 8/21/2026
• Dividend Payable: 9/11/2026
• Today: 10/29/2026
• Next Earnings (Estimated): 11/03/2026
• Record date for 12/11 Dividend: 11/20/2026
• Ex-Dividend for 12/11 Dividend: 11/20/2026
• Dividend Payable: 12/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AMGN
• CIK: 318154
• Web: www.amgen.com
• Phone: (805) 447-1000
• Fax: 805-447-1010
• Employees: 31,500
• Year Founded: 1980

Price Target and Rating

• Average Price Target for Amgen: $389.71
• High Price Target: $500.00
• Low Price Target: $200.00
• Potential Upside/Downside: -15.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.30
• Research Coverage: 30 Analysts

Profitability

• EPS (Trailing Twelve Months): $16.09
• Trailing P/E Ratio: 28.63
• Forward P/E Ratio: 20.07
• P/E Growth: 3.21
• Net Income: $7.71 billion
• Net Margins: 22.95%
• Pretax Margin: 27.00%
• Return on Equity: 124.14%
• Return on Assets: 13.18%

Debt

• Debt-to-Equity Ratio: 4.44
• Current Ratio: 1.37
• Quick Ratio: 1.13

Sales & Book Value

• Annual Sales: $38.10 billion
• Price / Sales: 6.54
• Cash Flow: $35.47 per share
• Price / Cash Flow: 12.99
• Book Value: $16.08 per share
• Price / Book: 28.65

Miscellaneous

• Outstanding Shares: 540,632,000
• Free Float: 536,037,000
• Market Cap: $249.09 billion
• Optionable: Optionable
• Beta: 0.41